Redeye comments on Beyond Frames order of SEK1.3m from a Chinese company.
Redeye states that the Q3 report came in somewhat below estimates but that the underlying developmen...
Redeye updates on G5 ahead of its Q3-results (due 9 November) where we expect sequential growth as t...
Redeye lowers its Base Case slightly in light of the recent financing agreement, which could bring X...
Starka bidrag från förvärv Beijer Alma omsatte 1 483 mkr i Q3, motsvarande en tillväxt y/y om 31%.
Teckningskurs 3,02 kr per aktie – 12-13% utspädning Med ca 101 miljoner nya aktier och teckningskurs...
Efter starka pandemi-kvartal har lönsamheten nu börjat pressas vilket straffade aktien.
The Thermo Fisher divorce raise many questions and several remains after the Q3 update on the 31st O...
Redeye leaves a comment on the Q3 report published by Alzinova earlier today.
Pihlajalinna reports Q3 results on Nov 4. We still expect Q3 EBITA to have remained a bit muted, but...
Redeye returns with an updated view of Stille following the Q3 2022 report.
Redeye updates on Evolution post Q3-results which came in stronger than expected driven by better th...
Redeye makes forecast adjustments following Binero’s Q3 2022 report, which saw revenues somewhat bel...
Redeye reassesses the case and updates its estimates after Sivers' Q3’22 report, which came in weake...
Urb-it’s Q3’22 report was mixed, with better-than-expected cost control but lower sales.
Q3 net sales were 3% above Refinitiv consensus. The company has not faced any remarkable demand weak...
Tillväxt på alla plan CAG levererar ett starkt tredje kvartal, vilket normalt är det säsongsmässigt ...
Faron has announced an interim trial update from the phase I/II BEXMAB study with lead candidate Bex...
Mediadelen fortsätter att gå bra medan padeln tynger Nettoomsättningen var oförändrad jämfört med sa...
Stark Q3 rapport ITAB redovisade en genomgående stark Q3-rapport.
